| Background and objection:Coronavirus disease 2019(COVID-19)is the third coronavirus disease after severe acute respiratory syndrome(SARS)and middle east respiratory syndrome(MERS)in human living environment in the past 20 years.COVID-19 is a coronavirus disease caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).SARS-CoV-2 is a single-stranded RNA virus with high infectivity,which can spread rapidly through the air in the population and cause severe respiratory syndrome in the human body,leading to serious and fatal respiratory disease outbreaks.SARS-CoV-2vaccination is important to prevent severe virus infection,but SARS-CoV-2 vaccination may induce corresponding immune response,especially in autoimmune diseases.Ankylosing spondylitis(AS)is a chronic inflammatory disease,which is often accompanied by psychological disease and decreased immune function.Therefore,it is necessary for AS patients to receive COVID-19 vaccine.However,there is no relevant research report on the safety of AS patients receiving SARS-CoV-2 vaccine and whether it will affect the relevant serological indicators and psychological status of such patients.Therefore,this article aims to explore the safety,related serological indicators and changes in psychological status of AS patients receiving SARS CoV-2 vaccine(novel coronavirus inactivated vaccine,Vero cell,Beijing Kexing).Materials and Methods:This study is a retrospective case-control study.According to the inclusion and exclusion criteria,the patients with AS who were hospitalized in the outpatient department of Rheumatology and Immunology Department of Yibin First People’s Hospital from April 2021 to December 2022 were screened,and the relatives of patients without chronic diseases were selected as the healthy control group of this study.The safety of SARS CoV-2 vaccine in AS patients and healthy control group was analyzed(group comparison and self control).The evaluation index is the incidence of adverse reactions and changes of relevant serological indicators in AS patients within 1month after receiving SARS-CoV-2 vaccine.Analyze the impact of SARS-CoV-2 vaccination on the mental health of AS patients(inter-group comparison)by using the AS cases without SARS-CoV-2vaccination and the AS cases with SARS vaccination generated by the tendency matching(matching factors include age,sex and the Bath ankylosing spondylitis disease activity index(BASDAI)(the evaluation scale is the Depression Anxiety Stress Scale Influence of [Depression Anxiety and Depression Scales-21,DASS-21] and Hospital Anxiety and Depression Scale(HADS).Result:1.Safety evaluation of SARS-CoV-2 vaccine in patients with ASA total of 82 eligible AS patients and 100 healthy controls were retrospectively included in this study.Statistical analysis showed that the two groups had similar demographic characteristics,including age,gender,education level,marital status,and common basic diseases(hypertension,diabetes,and coronary heart disease)(P>0.05).Of the 82 patients with AS,14(17.1%)were not vaccinated with SARS-CoV-2vaccine,and the remaining 68(82.9%)were vaccinated with the third dose of SARS-CoV-2 vaccine.In the 100 healthy control group,11(11.0%)healthy people were not vaccinated with SARS-CoV-2 vaccine,and the remaining 89(89.0%)healthy people were vaccinated with the third dose of SARS-CoV-2 vaccine.Compared with the healthy control group,the proportion of adverse events after the first dose,the second dose and the third dose of vaccine were(4.4% vs 5.6%),(14.7%vs 14.6%)and(19.1% vs 17.8%)respectively.There was no statistically significant difference in the incidence of adverse reactions in AS patients compared with the healthy control group(P>0.05).The most common adverse reactions were pain at the injection site and muscle soreness.All adverse events were transient,mild and moderate,and none of them needed hospitalization.Relevant serological indexes(erythrocyte sedimentation rate,hypersensitive C-reactive protein,creatinine,endogenous creatinine clearance rate,alanine aminotransferase,aspartate transferase,total bilirubin,triglyceride,plasma prothrombin time,activated fraction thrombin time,thrombin time,plasma fibrinogen determination,neutrophil count,platelet count,lymphocyte count)of AS patients vaccinated with SARS-CoV-2 vaccine There was no significant change(P>0.05).However,the white blood cell count of subjects after the second dose of SARS-CoV-2 vaccine was significantly lower than that before the vaccination,but most of the white blood cell counts were still within the normal medical reference range,which was not clinically significant and statistically significant(P<0.05).2.Effects of SARS-CoV-2 vaccine on psychological status of patients with ASThrough propensity score matching,14 AS patients vaccinated with SARS-CoV-2vaccine were included in the psychological status analysis as the experimental group.The two groups had similar demographic and basic clinical characteristics(P>0.05).The results of DASS-21 showed that the anxiety and depression levels of AS patients were significantly higher after receiving SARS-CoV-2 vaccine(P<0.05).Using the HADS questionnaire,it was also observed that the degree of anxiety and depression of AS patients after receiving SARS-CoV-2 vaccine increased significantly(P<0.05).Conclusion:1.It is generally safe for patients with AS to receive SARS-CoV-2 vaccine.2.Compared with the healthy control group,the vaccination of SARS-CoV-2 vaccine may increase the anxiety,depression and stress of AS patients. |
PDF Full Text Request